Article
Oncology
Hidetoshi Hayashi, Masakazu Ogura, Takashi Niwa, Toshihide Yokoyama, Junko Tanizaki, Tomohiro Ozaki, Hiroshige Yoshioka, Takayasu Kurata, Yosuke Tamura, Yasuhito Fujisaka, Kaoru Tanaka, Yoshikazu Hasegawa, Keita Kudo, Yasutaka Chiba, Kazuhiko Nakagawa
Summary: The combination of cisplatin plus nab-paclitaxel with concurrent thoracic radiotherapy for locally advanced NSCLC showed promising feasibility and activity, warranting further investigation.
Article
Oncology
Pierre Loap, Delphine Loirat, Frederique Berger, Kim Cao, Francesco Ricci, Anne Jochem, Laurence Raizonville, Veronique Mosseri, Alain Fourquet, Youlia Kirova
Summary: The RADIOPARP Phase I trial evaluating Olaparib associated with breast radiotherapy in TNBC patients demonstrated an excellent toxicity profile with few low-grade adverse events, suggesting the combination therapy's potential efficacy and safety.
INTERNATIONAL JOURNAL OF CANCER
(2021)
Article
Oncology
Huei-Tyng Huang, Michael G. Nix, Douglas H. Brand, David Cobben, Crispin T. Hiley, John D. Fenwick, Maria A. Hawkins
Summary: The study investigates the effects of different treatment schedules on tumor repopulation and alpha/beta ratio in radiotherapy and chemo-radiotherapy for locally advanced non-small cell lung cancer. The findings suggest that shorter duration of concurrent chemo-radiotherapy and moderate hypofractionation within normal tissue toxicity limits could improve the efficacy of the treatment.
Article
Oncology
Wai-Tong Ng, Cheuk-Wai Choi, Barton But, Roger K. C. Ngan, Stewart Tung, Ashley C. Cheng, Dora L. W. Kwong, Tai-Xiang Lu, Anthony T. C. Chan, Harry Yiu, Sarah Lee, Frank Wong, Kam-Tong Yuen, Richard J. Chappell, Anne W. M. Lee
Summary: The combination of cisplatin-based induction or adjuvant chemotherapy with concurrent chemoradiotherapy has been found to improve overall survival in patients with locoregionally advanced nasopharyngeal carcinoma. The optimal platinum doses for the concurrent and induction/adjuvant phases were determined to be 160 mg/m(2) and 260 mg/m(2) respectively.
CLINICAL CANCER RESEARCH
(2022)
Article
Oncology
Li-Ting Liu, Huai Liu, Ying Huang, Jin-Hao Yang, Si-Yi Xie, Yuan-Yuan Li, Shan-Shan Guo, Bin Qi, Xiao-Yun Li, Dong-Ping Chen, Feng Jin, Xue-Song Sun, Zhen-Chong Yang, Sai-Lan Liu, Dong-Hua Luo, Ji-Bin Li, Qing Liu, Pan Wang, Ling Guo, Hao-Yuan Mo, Fang Qiu, Qi Yang, Yu-Jing Liang, Guo-Dong Jia, Dong-Xiang Wen, Jin-Jie Yan, Chong Zhao, Qiu-Yan Chen, Rui Sun, Lin-Quan Tang, Hai-Qiang Mai
Summary: The efficacy and safety of concurrent adjuvant cisplatin-gemcitabine were compared with cisplatin-fluorouracil in N2-3 nasopharyngeal carcinoma. The 3-year progression-free survival was significantly higher in the cisplatin-gemcitabine group (83.9%) compared to the cisplatin-fluorouracil group (71.5%). The adverse events were similar between the two groups. Therefore, cisplatin-gemcitabine could be considered as an adjuvant therapy option for patients with N2-3 nasopharyngeal carcinoma.
Article
Medicine, Research & Experimental
Jianwen Gao, Zehua Wang, Jiayu Fu, A. Jisaihan, Yuko Ohno, Congjian Xu
Summary: Ovarian cancer is the most lethal type of gynecological cancer with a low 5-year survival rate. Chemotherapy resistance is a key constraint in improving the cure rate of ovarian cancer. This study found that the combination of olaparib and cisplatin had a higher inhibition effect on ovarian cancer cells, particularly exhibiting significant synergistic effects at low doses.
EXPERIMENTAL AND THERAPEUTIC MEDICINE
(2021)
Article
Oncology
Hamid Sheikh, David Ryder, Andrew Bateman, Anthony Chalmers, Andrew Jackson
Summary: This study investigated the therapeutic effect of Olaparib in patients with oesophageal cancer. The results showed that the dose of 100 mg twice daily exceeded the maximum tolerated dose, while 50 mg twice daily may be the maximum tolerated dose.
CLINICAL AND TRANSLATIONAL RADIATION ONCOLOGY
(2023)
Article
Oncology
Kazumasa Akagi, Hirokazu Taniguchi, Minoru Fukuda, Takuya Yamazaki, Sawana Ono, Hiromi Tomono, Takayuki Suyama, Midori Shimada, Hiroshi Gyotoku, Shinnosuke Takemoto, Hiroyuki Yamaguchi, Yosuke Dotsu, Hiroaki Senju, Hiroshi Soda, Takashi Mizowaki, Yoshio Monzen, Takaya Ikeda, Seiji Nagashima, Yutaro Tasaki, Daisuke Nakamura, Kazutoshi Komiya, Katsumi Nakatomi, Eisuke Sasaki, Koichi Hirakawa, Hiroshi Mukae
Summary: This study aims to investigate the efficacy and toxicities of amrubicin plus cisplatin combined with concurrent accelerated hyperfractionated thoracic radiotherapy in the treatment of unresectable limited-disease small cell lung cancer patients.
Article
Oncology
Jennifer R. Bellon, Yu-Hui Chen, Rebecca Rees, Alphonse G. Taghian, Julia S. Wong, Rinaa S. Punglia, Ron Y. Shiloh, Laura E. G. Warren, Monica S. Krishnan, John Phillips, Jennifer Pretz, Rachel Jimenez, Stephanie Macausland, Itai Pashtan, Chelsea Andrews, Steven J. Isakoff, Eric P. Winer, Sara M. Tolaney
Summary: The study aimed to evaluate the safety of cisplatin with radiation therapy in patients with early-stage TNBC, determining the maximum tolerated dose and recommending appropriate doses for different surgical approaches.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2021)
Editorial Material
Oncology
Jose Perez-Garcia, Maria Gion, Javier Cortes
Summary: The phase II studies on breast cancer using the I-SPY2 platform have shown promising results in accelerating the development of new treatments. Adding durvalumab and olaparib to standard neoadjuvant chemotherapy significantly increased the pathological complete response rate in HER2-negative breast cancer patients, regardless of hormone receptor status.
Article
Oncology
Hui Jiang, Qiaoqiao Li, Baoqing Chen, Mian Xi, Kanjiebubi Makelike, Shiliang Liu, Yonghong Hu, Yujia Zhu
Summary: This study aimed to evaluate the safety, dose-limiting toxicity, maximum tolerated dose, and preliminary effect of nanoparticle albumin-bound paclitaxel in combination with concurrent chemoradiotherapy in patients with locally advanced esophageal squamous cell carcinoma. The results showed that this treatment regimen was effective and well-tolerated for patients with locally advanced esophageal squamous cell carcinoma.
Article
Oncology
Janita E. van Timmeren, Stefanie Ehrbar, Madalyne Chamberlain, Michael Mayinger, Mischa S. Hoogeman, Nicolaus Andratschke, Matthias Guckenberger, Stephanie Tanadini-Lang
Summary: A single-isocenter SBRT technique for lung patients with multiple targets results in clinically acceptable increases in normal lung dose.
RADIOTHERAPY AND ONCOLOGY
(2022)
Article
Oncology
Bo Qiu, DaQuan Wang, QiWen Li, YingJia Wu, SuPing Guo, XiaoBo Jiang, JianLan Fang, JinYu Guo, FangJie Liu, Chu Chu, Bin Wang, Li Chen, Jun Zhang, YiMei Liu, YongHong Hu, Hui Liu
Summary: The study evaluated the efficacy and safety of nimotuzumab combined with CCRT in patients with unresectable squamous cell lung cancer. Results showed that the NIMO-CCRT group had a lower risk of brain metastasis and similar OS and PFS compared to the CCRT group. Further investigations are needed to confirm these findings.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2021)
Review
Endocrinology & Metabolism
Xiangyu Chen, Yang Pan, Qihua Wang, Congzhe Ren, Muwei Li, Xuexue Hao, Lijun Xie, Xiaoqiang Liu
Summary: The study conducted a network meta-analysis on olaparib, olaparib plus abiraterone, and NAA, finding that olaparib performed better in terms of rPFS compared to apalutamide plus abiraterone, but there was no significant difference in rPFS between olaparib plus abiraterone and either olaparib or apalutamide plus abiraterone. Apalutamide plus abiraterone may be the most preferred intervention for managing adverse events.
FRONTIERS IN ENDOCRINOLOGY
(2023)
Article
Medicine, General & Internal
Yi-Hsuan Lai, Kai-Che Tung, San-Chi Chen
Summary: Actionable gene has not been discovered in HCC, but DDR gene mutation in HCC may have potential therapeutic implications for PARP inhibitors.
Article
Oncology
Lennart Kester, Danielle Seinstra, Annelot G. J. van Rossum, Claire Vennin, Marlous Hoogstraat, Daphne van der Velden, Mark Opdam, Erik van Werkhoven, Kerstin Hahn, Iris Nederlof, Ester H. Lips, Ingrid A. M. Mandjes, A. Elise Van Leeuwen-Stok, Sander Canisius, Harm van Tinteren, Alex L. T. Imholz, Johanneke E. A. Portielje, Monique E. M. M. Bos, Sandra D. Bakker, Emiel J. Rutgers, Hugo M. Horlings, Jelle Wesseling, Emile E. Voest, Lodewyk F. A. Wessels, Marleen Kok, Hendrika M. Oosterkamp, Alexander van Oudenaarden, Sabine C. Linn, Jacco van Rheenen
Summary: Extensive work in preclinical models shows that microenvironmental cells, including specific populations of immune and epithelial cells, influence cancer cell behavior and patient outcomes. By analyzing single-cell sequencing data and using deconvolution algorithms, researchers identified various cell types in the microenvironment that impact differential survival and treatment benefit in patients with breast cancer.
CLINICAL CANCER RESEARCH
(2022)
Article
Oncology
Louisa R. Hoes, Jade M. van Berge Henegouwen, Hanneke van der Wijngaart, Laurien J. Zeverijn, Daphne L. van der Velden, Joris van de Haar, Paul Roepman, Wendy J. de Leng, Anne M. L. Jansen, Erik van Werkhoven, Vincent van der Noort, Alwin D. R. Huitema, Eelke H. Gort, Jan Willem B. de Groot, Emile D. Kerver, Derk Jan de Groot, Frans Erdkamp, Laurens Beerepoot, Mathijs P. Hendriks, Egbert F. Smit, Winette T. A. van der Graaf, Carla M. L. van Herpen, Mariette Labots, Ann Hoeben, Hans Morreau, Martijn P. Lolkema, Edwin Cuppen, Hans Gelderblom, Henk M. W. Verheul, Emile E. Voest
Summary: This study suggests that patients with rare cancers can benefit from approved drugs similar to common cancers. Molecular testing in rare cancer patients may identify treatment opportunities and clinical benefits.
CLINICAL CANCER RESEARCH
(2022)
Article
Hematology
Chantal Visser, Maurice Swinkels, Erik D. van Werkhoven, F. Nanne Croles, Heike S. Noordzij-Nooteboom, Matthijs Eefting, Suzanne M. Last-Koopmans, Cecile Idink, Peter E. Westerweel, Bart Santbergen, Pieter A. Jobse, Fazil Baboe, Peter A. W. Te Boekhorst, Frank W. G. Leebeek, Mark-David Levin, Marieke J. H. A. Kruip, A. J. Gerard Jansen
Summary: This study aimed to investigate the effects of COVID-19 vaccination in patients with immune thrombocytopenia (ITP). The results showed that COVID-19 vaccination had minimal impact on platelet count and bleeding complications in ITP patients, but some patients experienced exacerbation of their condition. Risk factors for ITP exacerbation included low platelet count, ITP treatment at the time of vaccination, and age.
Article
Oncology
Ariane A. van Loevezijn, Marieke E. M. van der Noordaa, Marcel P. M. Stokkel, Erik D. van Werkhoven, Emma J. Groen, Claudette E. Loo, Paula H. M. Elkhuizen, Gabe S. Sonke, Nicola S. Russell, Frederieke H. van Duijnhoven, Marie-Jeanne T. F. D. Vrancken Peeters
Summary: In cN+ breast cancer patients, response-adjusted axillary treatment according to the MARI-protocol prevented ALND in 80% of patients and resulted in an excellent three-year aRFI of 98%.
BREAST CANCER RESEARCH AND TREATMENT
(2022)
Article
Respiratory System
Jaimy Klijnhout, Denise Mannee, Michel van den Heuvel, Bram van den Borst, Hanneke van Helvoort
Summary: The study aims to determine the accuracy of unsupervised home-based measurements of inspiratory capacity (IC) and dynamic hyperinflation (DH) in COPD patients. The results show that after training and learning, patients are able to perform accurate measurements, which contribute to the assessment of DH.
COPD-JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE
(2022)
Article
Oncology
K. van den Berg, D. P. Schaap, E. L. K. Voogt, T. E. Buffart, H. M. W. Verheul, J. W. B. de Groot, C. Verhoef, J. Melenhorst, J. M. L. Roodhart, J. H. W. de Wilt, H. L. van Westreenen, A. G. J. Aalbers, M. van't Veer, C. A. M. Marijnen, J. Vincent, L. H. J. Simkens, N. A. J. B. Peters, M. Berbee, I. M. Werter, P. Snaebjornsson, H. M. U. Peulen, I. G. van Lijnschoten, M. J. Roef, G. A. P. Nieuwenhuijzen, J. G. Bloemen, J. M. W. E. Willems, G. J. M. Creemers, J. Nederend, H. J. T. Rutten, J. W. A. Burger
Summary: The study aims to evaluate the complete response rate in high-risk locally advanced rectal cancer patients after intensified chemotherapy prior to neoadjuvant chemoradiotherapy.
Article
Multidisciplinary Sciences
Frederik A. van Delft, Milou Schuurbiers, Mirte Muller, Sjaak A. Burgers, Huub H. van Rossum, Maarten J. IJzerman, Hendrik Koffijberg, Michel M. van den Heuvel
Summary: This study compares nine prediction methods using longitudinal tumor biomarker data to accurately and with a low false positive rate predict non-response to immunotherapy in NSCLC patients. The study evaluated nine models of varying complexity and demonstrated the usefulness of longitudinal biomarker data in predicting treatment response.
Article
Oncology
Ariane A. A. van Loevezijn, Charissa S. S. Geluk, Marieke J. J. van den Berg, Erik D. D. van Werkhoven, Marie-Jeanne T. F. D. Vrancken Peeters, Frederieke H. H. van Duijnhoven, Marije J. J. Hoornweg
Summary: This study aimed to evaluate the surgical outcomes of immediate and delayed oncoplastic surgery (OPS). The study found that selecting delayed OPS allowed for re-excision of margins without dismantling the reconstruction, achieving excellent breast conservation rates.
BREAST CANCER RESEARCH AND TREATMENT
(2023)
Article
Oncology
Floor Piqeur, Britt J. P. Hupkens, Stefi Nordkamp, Marnix G. Witte, Philip Meijnen, Heleen M. Ceha, Maaike Berbee, Margriet Dieters, Sofia Heyman, Alexander Valdman, Martin P. Nilsson, Joost Nederend, Harm J. T. Rutten, Jacobus W. A. Burger, Corrie A. M. Marijnen, Heike M. U. Peulen
Summary: This study presents the first consensus-based delineation guideline for locally recurrent rectal cancer (LRRC). Multidisciplinary evaluation is beneficial in determining target volumes. Further analysis of re-recurrences is needed to optimize the delineation guidelines.
RADIOTHERAPY AND ONCOLOGY
(2022)
Article
Oncology
Elisabeth M. Smale, Bas van Vlijmen, Hadewig B. B. Colen, Michel M. van den Heuvel, Ingrid M. E. Desar, Bart J. F. van den Bemt, Charlotte L. Bekker
Summary: This study evaluates the feasibility of an individualized dispensing program to prevent waste of oral anticancer drugs. The results from the first batch of participants show that the individualized dispensing program is effective in terms of implementation, acceptability, practicality, effect, and demand.
JCO ONCOLOGY PRACTICE
(2023)
Article
Oncology
A. Vera de Jonge, Erik van Werkhoven, Avinash G. Dinmohamed, Marcel Nijland, Aeilko H. Zwinderman, Patrick M. Bossuyt, Martine S. Veldhuis, Emma G. G. M. Rutten, Rogier Mous, Joost S. P. Vermaat, Yorick Sandberg, Eva de Jongh, Yavuz M. Bilgin, Rinske Boersma, Harry Koene, Marie Jose Kersten, Daphne de Jong, Martine E. D. Chamuleau
Summary: In a study conducted in the Netherlands, researchers found that R2CHOP treatment significantly improved the prognosis of DLBCL patients compared to R-CHOP treatment, based on a non-randomized risk-adjusted comparison.
BLOOD CANCER JOURNAL
(2023)
Article
Oncology
Sonja Vliek, Florentine S. Hilbers, Erik van Werkhoven, Ingrid Mandjes, Rob Kessels, Sieta Kleiterp, Esther H. Lips, Lennart Mulder, Mutamba T. Kayembe, Claudette E. Loo, Nicola S. Russell, Marie-Jeanne T. F. D. Vrancken Peeters, Marjo J. Holtkamp, Margaret Schot, Joke W. Baars, Aafke H. Honkoop, Annelie J. E. Vulink, Alex L. T. Imholz, Suzan Vrijaldenhoven, Franchette W. P. J. van den Berkmortel, Jetske M. Meerum Terwogt, Jolanda G. Schrama, Philomeen Kuijer, Judith R. Kroep, Annemieke van der Padt-pruijsten, Jelle Wesseling, Gabe S. Sonke, Kenneth G. A. Gilhuijs, Agnes Jager, Petra Nederlof, Sabine C. Linn
Summary: This study aimed to investigate the sensitivity of BRCA-altered breast cancer to high-dose alkylating chemotherapy. The results showed no significant difference in neoadjuvant response, recurrence-free survival, and overall survival between high-dose and conventional chemotherapy in patients with BRCA-altered tumors. Further research is needed to determine if there are patients with BRCA-altered breast cancer who can benefit from high-dose chemotherapy.
Article
Surgery
Stefi Nordkamp, Jan M. van Rees, Kim van den Berg, David M. Mens, Davy M. J. Creemers, Heike M. U. Peulen, Geert-Jan Creemers, Grard A. P. Nieuwenhuijzen, Jip L. Tolenaar, Johanne G. Bloemen, Joost Rothbarth, Harm J. T. Rutten, Cornelis Verhoef, Jacobus W. A. Burger
BRITISH JOURNAL OF SURGERY
(2023)
Article
Surgery
Stefi Nordkamp, Floor Piqeur, Kim van den Berg, Jip L. Tolenaar, Irene E. G. van Hellemond, Geert-Jan Creemers, Mark Roef, Gesina van Lijnschoten, Jeltsje S. Cnossen, Grard A. P. Nieuwenhuijzen, Johanne G. Bloemen, Lien Coolen, Joost Nederend, Heike M. U. Peulen, Harm J. T. Rutten, Jacobus W. A. Burger
Summary: This study aimed to evaluate the oncological outcomes of patients with locally recurrent rectal cancer with a pCR, and compare them with patients without a pCR. Patients with a pCR had superior oncological outcomes. A watch-and-wait approach may be considered in highly selected patients to improve quality of life without compromising oncological outcomes.
BRITISH JOURNAL OF SURGERY
(2023)
Article
Urology & Nephrology
Hielke M. de Vries, Sarah R. Ottenhof, Tynisha S. Rafael, Erik van Werkhoven, Floris J. Pos, Bas W. G. van Rhijn, Luc M. F. Moonen, Niels Graafland, Jeantine M. de Feijter, Eva E. Schaake, Simon Horenblas, Oscar R. Brouwer
Summary: A retrospective analysis of 228 patients with penile cancer who underwent pelvic lymph node treatment showed a high recurrence rate and poor prognosis after pelvic treatment, emphasizing the need for more effective systemic treatment strategies.
EUROPEAN UROLOGY OPEN SCIENCE
(2023)